Janssen, High Wycombe, Bucks, UK.
Diabetes UK Wells Lawrence House, London, UK.
Endocrinol Diabetes Metab. 2020 Dec 6;4(2):e00207. doi: 10.1002/edm2.207. eCollection 2021 Apr.
Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource-intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at-risk populations and/or disease progression. Novel clinical trial designs could lead to reduced costs of development and less burden to patients, due to shorter trial duration, and/or less burdensome assessments.
开发用于治疗 2 型糖尿病 (T2D) 的新型治疗产品是一个漫长而资源密集的过程。新型生物标志物有可能通过缩短临床试验或更好地预测高危人群和/或疾病进展，从而辅助临床试验设计。由于临床试验持续时间更短，以及/或评估负担更小，新型临床试验设计可降低开发成本并减轻患者负担。
